By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Catabasis Pharmaceuticals, Inc. 

161 First Street
Suite 1A
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-349-1971 Fax: 617-273-2637



Company News
Muscular Dystrophy Association To Collaborate With Catabasis Pharma On Development Of CAT-1004, A Potential Novel Oral Disease-Modifying Treatment For Duchenne Muscular Dystrophy 2/5/2016 9:14:39 AM
Catabasis Pharmaceuticals, Inc. Announces Positive Top-Line Results From Part A Of The Movedmd Trial, A Phase I/II Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 1/25/2016 8:13:19 AM
FARA Announces Catabasis Pharmaceuticals, Inc.As The Recipient Of The Kyle Bryant Translational Research Award To Evaluate CAT-4001 As A Potential Therapy For Friedreich’s Ataxia 1/19/2016 8:18:27 AM
Catabasis Pharmaceuticals, Inc. Completes Enrollment For Part A Of The Movedmdsm Trial, A Phase I/II Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 12/18/2015 10:25:57 AM
Catabasis Pharmaceuticals, Inc. Names Deirdre Cunnane SVP, General Counsel 12/17/2015 9:54:23 AM
Catabasis Pharmaceuticals, Inc. Announces First Patient Dosed In Phase IIa Trial Of CAT-2054 For The Treatment Of Hypercholesterolemia 12/9/2015 8:51:43 AM
Catabasis Pharmaceuticals, Inc. To Present At The Oppenheimer 26th Annual Healthcare Conference 12/2/2015 10:47:11 AM
Catabasis Pharmaceuticals, Inc. And Actigraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy 11/19/2015 10:29:34 AM
Catabasis Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results And Recent Corporate Highlights 11/13/2015 11:24:04 AM
Catabasis Pharmaceuticals, Inc. Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The Action Duchenne International Conference 10/27/2015 10:55:23 AM